Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
The ability of the population to remain synchronized as well as the ability of single cells to generate oscillations is composed in VIP or VIP receptor deficient mice. While not highly studied, there is evidence that levels of VIP and its receptor may vary depending on each circadian oscillation. The leading hypothesis of VIP function points to the neurons using VIP to communicate with specific postsynaptic targets to regulate circadian rhythm. The depolarization of the VIP-expressing neurons by light appears to cause the release of VIP and co-transmitters (including GABA) that can in turn, alter the properties of the next set of neurons with the activation of VPAC2. Another hypothesis supports VIP sending a paracrine signal from a distance rather than the adjacent postsynaptic neuron.
== Chemistry == The chemical structure of suvomipic was originally undisclosed for a time. The drug has been patented and its structure was initially said to be known only to Pelage Pharmaceuticals. The company has also patented and published on other MPC inhibitors such as JXL069 and JXL082. They are (E)-2-cyano-3-(1H-indol-3-yl)acrylic acids and related analogues. Suvomipic was said to be neither JXL069 nor JXL082. The drug-related properties of certain related MPC inhibitors like UK-5099 (JXL001) are said to be incompatible with therapeutic use. In July 2026, the INNTooltip International Nonproprietary Name of suvomipic was published and revealed it to in fact be JXL069.
== Personal life == On 5 July 2008, Emma Griffiths married Busted member Matt Willis at Rushton Hall, Northamptonshire, after three years of dating. The wedding was featured in OK magazine. She gave birth to their first child, a daughter named Isabelle, on 20 June 2009. On 25 November 2011, the couple had a second child, a son named Ace. On 4 May 2016, Willis gave birth to their third child, a second daughter, named Trixie Grace. In an episode of Who Do You Think You Are?, Willis confirmed that she has longstanding roots in Birmingham, with her family tree being traced back to her great-great-great-grandfather, who was named James Gretton and was listed as a Horn and Hair Merchant in the census records. She also found she had Irish ancestors, a fact that came as a surprise to her. The revelations about her ancestry left her extremely uncomfortable with the actions of one, who she discovered was a violent Orangeman, but overall, she was happy to have found a connection to her more broad Irish heritage. Willis is a supporter of Aston Villa. In August 2019, Willis obtained a qualification as a maternity care assistant following her experience on the W series Delivering Babies. During the COVID-19 pandemic in March 2021, Willis and her husband completed training with St John Ambulance to act as vaccination volunteers. In May 2023, Willis was featured in the documentary, Matt Willis: Fighting Addiction. The documentary, which aired on the BBC on 17 May 2023, followed Willis and her husband as they spoke about the latter's addiction issues.
Sources: en.wikipedia.org
In December 2017, he signed Tax Reform for Acceleration and Inclusion Law (TRAIN Law) which excludes those earning an annual taxable income of ₱250,000 and below from paying the personal income tax, while raising higher excise taxes on vehicles, sugar-sweetened beverages, petroleum products, tobacco and other non-essential goods. Revenues collected from the TRAIN law will help fund the administration's massive infrastructure program. In March 2021, to attract more investments and maintain fiscal stability, Duterte signed the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act, reducing the 30 percent corporate income tax rate to 25 percent for firms with assets above ₱100 million and to 20 percent for smaller firms. Duterte raised sin taxes on tobacco and vapor products in July 2019, and alcohol beverages and electronic cigarettes in January 2020, to fund the Universal Health Care Act and reduce incidence of deaths and diseases associated with smoking and alcohol consumption. Duterte's tax reform program has garnered both support and criticism. Critics have argued that the administration's tax policy would burden the poor. The implementation of the TRAIN Law triggered protests from various left-wing groups. On January 15, 2018, protesters gathered at various public market sites, calling for the revocation of TRAIN. However, proponents of the program cite its appeal to foreign investors and economic benefits as the main reasons behind tax reform.
These hazards in insects can be controlled in various ways. Allergic hazards can be labelled on the packaging to avoid consumption by susceptible consumers. Selective farming can be used to minimize chemical hazards, whereas microbial and parasitical hazards can be controlled by cooking processes.
== History == The syndrome is named after Edward Treacher Collins (1862–1932), the English surgeon and ophthalmologist who described its essential traits in 1900. In 1949, Adolphe Franceschetti and David Klein described the same condition on their own observations as mandibulofacial dysostosis. The term mandibulofacial dysostosis is used to describe the clinical features.
=== Religious organizations === Celtic Reconstructionism, a form of Polytheism Congregation of Clerics Regular of the Divine Providence (Theatines), a Roman Catholic religious order Community of the Resurrection, an Anglican religious order Congregation of the Resurrection, a Catholic religious order
Sources: en.wikipedia.org
=== Proposed amalgamation === By early May 2026, several district and regional councils in Northland, Taranaki, the West Coast, Waikato, the Bay of Plenty, Wellington Wairarapa, Hawke's Bay and Southland Regions were discussing options to merge into unitary authorities as part of the Sixth National Government's policy of "simplifying" local government. On 5 May, the Local Government Minister Simon Watts and the RMA Reform Minister Chris Bishop issued local councils with a three-month timeframe to come up with amalgamation plans under the new "Head Start" approach. These amalgamation plans replaced the earlier proposed "combined territorial boards" and would be assessed by the newly-established Ministry for Cities, Environment, Regions and Transport (MCERT). The Government's 2026 amalgamation ultimatum received support from several local government leaders including Mayor of Nelson Nick Smith, Mayor of Southland Rob Scott, Mayor of Timaru Nigel Brown, Mayor of South Wairarapa Dame Fran Wilde, Mayor of Whangārei Ken Couper, Mayor of New Plymouth Max Brough, and Mayor of Invercargill Tom Campbell. By contrast, Mayor of Gore Ben Bell and Mayor of Rotorua Tania Tapsell expressed reservations about merger and the short time-frame. Meanwhile Mayor of Tasman Tim King preferred that the central government decide the local government model rather than delegating it to local councils.
Receptors of a particular type are linked to specific cellular biochemical pathways that correspond to the signal. While numerous receptors are found in most cells, each receptor will only bind with ligands of a particular structure. This has been analogously compared to how locks will only accept specifically shaped keys. When a ligand binds to a corresponding receptor, it activates or inhibits the receptor's associated biochemical pathway, which may also be highly specialised. Receptor proteins can be also classified by the property of the ligands. Such classifications include chemoreceptors, mechanoreceptors, gravitropic receptors, photoreceptors, magnetoreceptors and gasoreceptors.
With ring-opening polymerization, automated synthesis has been used for rapid screening and optimization, including with catalyst + initiator systems and their polymerization conditions. For example, Hoogenboom et al. determined the optimal temperature for the polymerization of 2-ethyl-2-oxazoline in dimethylacetamide (DMAc), allowing for individual heating of the parallel reactors, which shortened the time needed for preparation and analysis. To aid with the catalyst research for polyolefins, Symyx Technologies Inc. used automated synthesis to create a library of palladium and nickel catalysts, which were screened for ethylene polymerization. This process found that the largest polyethylene polymers were created by the complexes with the highest steric hindrance for the ortho-positions of the aryl rings, while electronic factors did not influence yield or molecular weight. In addition, Tuchbreiter and Mülhaupt used automated synthesis to demonstrate the improvements of minireactors for the polymerization of olefins, with quality improving as compared to utilizing simple arrays.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.